Xynomic Pharmaceuticals Holdings, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Xynomic Pharmaceuticals Holdings, Inc.
US-China biopharma is paying up to $800m to Boehringer Ingelheim in connection with in-licensing BI 860585, its second asset purchase from the German big pharma.
But Q4 was the third sequential quarter with a decrease in financing totals. A review of biopharma start-up dealmaking and financing activity from October through December 2017, based on data from Strategic Transactions.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.
- Other Names / Subsidiaries
- Bison Capital Acquisition Corp.
- Xynomic Pharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.